🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07291921
Recruiting Observational

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

NCT07291921 · tracked via the Priya Life Science China tracker
Sponsor
Peking University People's Hospital
Phase
Observational
Started
2025-05-08
Last updated
2026-03-03

Condition(s) studied

Lung NeoplasmsNeoadjuvant TherapyImmunotherapyMinimal Residual Disease

Study summary

This project aims to innovatively integrate multi-omics data, including plasma metabolomics, radiomics, and cfDNA multi-level information, combined with survival data (e.g., RFS), to establish a novel multidimensional approach for noninvasive postoperative recurrence monitoring in lung cancer using artificial intelligence algorithms. The goal is to develop a new noninvasive recurrence monitoring system for lung cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: 1. Signed written informed consent. 2. Male or female, aged ≥ 18 and \< 85 years. 3. Radical resection performed, pathologic stage IB-IIIA (8th TNM) non-small-cell lung cancer. 4. Tumor tissue and blood samples obtainable at all protocol-specified time-points. 5. No pure ground-glass nodule on imaging. 6. Completed standard neoadjuvant immunotherapy combined with platinum-based chemotherapy. Exclusion Criteria: 1. Postoperative pathology shows other than NSCLC, including but not limited to benign lesions, small-cell carcinoma, metastasis, or indeterminate/inadequate histology. 2. Insufficient or poor-quality blood or tissue samples. 3. Pure ground-glass nodule on imaging. 4. History of any malignancy within the past 5 years. 5. Contraindication to surgery preventing radical resection. 6. Non-radical (R2) resection. 7. Pathologic stage IIIB-N3, IIIC, or IV on paraffin sections. 8. Refusal or withdrawal of informed consent. 9. Any condition deemed unsuitable by the investigator (e.g., perioperative blood transfusion, severe psychiatric disorder precluding follow-up).

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Peking University People's Hospital Beijing Beijing Municipality Recruiting

More Peking University People's Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07291921 on ClinicalTrials.gov ↗ ← All trials in China